focus -WSS

focus

author：Wikipedia 2025-10-02 10:48:18 - browse：6

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： How digital tools helped lower hypertension in marginalized patients

WSS

Medicare Advantage proposed rates disappoint insurers

KalVista pill reduced swelling 'attacks' caused by genetic disease

Gilead might be held responsible for not developing a drug

PhRMA lawsuit over Medicare drug price negotiation tossed

The dental labor crisis is a moment of opportunity

Why the Crimean Bridge is key to Russia's war in Ukraine

focus

focus

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

'Reaching a detente': STAT's Helen Branswell on covering Covid

Sports medicine is finally prioritizing gender equality

What should King Charles tell the public about his cancer?

Anesthesiologist group: stop taking Ozempic before surgery

Gilead might be held responsible for not developing a drug

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare threatens to cut off funding for HCA's Mission hospital

After affirmative action ruling, medical educators look to 'holistic review'

Robert F. Kennedy is pitching centrism on health, even on abortion

hotspot

Resistance to cancer drugs: A new genetic explanation

Readout LOUD podcast: How biotech is using artificial intelligence

Senators start work on Medicare physician payment reform

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Celebrate National Dole Whip Day for 3 days this week at Disney

BioAge raises $170M for combination therapy with Zepbound

entertainment

hotspot

explore

hotspot